Humanwell Healthcare (Group)Ltd Management

Management criteria checks 4/4

Humanwell Healthcare (Group)Ltd's CEO is Xiafei Deng, appointed in Jun 2020, has a tenure of 3.92 years. directly owns 0.098% of the company’s shares, worth CN¥31.85M. The average tenure of the management team and the board of directors is 4.1 years and 8.5 years respectively.

Key information

Xiafei Deng

Chief executive officer

CN¥1.4m

Total compensation

CEO salary percentage	n/a
CEO tenure	3.9yrs
CEO ownership	0.1%
Management average tenure	4.1yrs
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO

Xiafei Deng (59 yo)

3.9yrs

Tenure

CN¥1,370,300

Compensation

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Xiafei Deng	President & Director	3.9yrs	CN¥1.37m	0.098% CN¥ 31.9m
Yajun Wu	CFO & VP	20.2yrs	CN¥1.01m	0.059% CN¥ 19.4m
Qianlun Li	VP & Secretary	11yrs	CN¥926.50k	0.019% CN¥ 6.1m
Wentao Du	Vice President	20.6yrs	CN¥1.30m	0.056% CN¥ 18.1m
Lie Li	Vice President	4.1yrs	CN¥1.21m	0.032% CN¥ 10.4m
Hongjie Zhang	Vice President	no data	CN¥1.18m	0.028% CN¥ 9.1m
Qiang Yin	Vice President	4.1yrs	CN¥912.00k	0.028% CN¥ 9.1m
Qun Yu	Vice President	3.6yrs	CN¥1.22m	0.028% CN¥ 9.1m

4.1yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 600079's management team is considered experienced (4.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Xiafei Deng	President & Director	25.3yrs	CN¥1.37m	0.098% CN¥ 31.9m
Min Qi	Supervisor	10yrs	no data	no data
Rui Zhou	Independent Director	3yrs	CN¥100.00k	no data
Lin Qing Liu	Independent director	4yrs	CN¥100.00k	no data
Xiao Dong Zhang	Director	27.3yrs	CN¥882.00k	0.029% CN¥ 9.3m
Xuehai Wang	Director	21yrs	CN¥180.00k	0.22% CN¥ 73.2m
Jie Li	Chairman of the Board	21yrs	CN¥2.00m	6.06% CN¥ 2.0b
Yue Xin Du	Chairman of the Supervisory Board	19.2yrs	CN¥66.00k	no data
Hansheng Zhou	Director	7.1yrs	no data	no data
Chenggang Zheng	Supervisor	4yrs	no data	no data
Kong Na	Representative Member of the Supervisory Board	4yrs	no data	no data
Xia Yuan	Employee Representative Member of the Supervisory Board	4yrs	no data	no data

8.5yrs

Average Tenure

54yo

Average Age

Experienced Board: 600079's board of directors are considered experienced (8.5 years average tenure).

Humanwell Healthcare (Group)Ltd Management

Management criteria checks 4/4

Key information

Recent management updates

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥1.32 (vs CN¥1.54 in FY 2022)

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.42 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings released: EPS: CN¥1.54 (vs CN¥0.83 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: CN¥0.58 (vs CN¥0.19 in 1Q 2021)

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥26.05

Investor sentiment improved over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

New 90-day high - CN¥38.00

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

New 90-day high - CN¥36.59

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age